NTLA - Mergers and acquisitions

Rewrite Therapeutics' proprietary and versatile DNA writing platform enables a range of novel genome editing strategiesAcquisition further expands Intellia's industry-leading genome editing toolbox by adding a platform that is highly complementary to its existing CRISPR/Cas9 and base editing technologies CAMBRIDGE, Mass., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics leveraging CRISPR-based technologies, today announced the acquisition of Rewrite Therapeutics, Inc. (Rewrite), a private biotechnology company focused on advancing novel DNA writing technologies. Rewrit